Nektar will disclose their financial figures for the second quarter on the date of August 7, 2025, following the closure of US-based financial markets.
Nektar Therapeutics, a clinical-stage biotechnology company based in San Francisco, California, has announced its second-quarter financial results for the year 2025. The announcement was made after the close of U.S.-based financial markets on Thursday, August 7, 2025.
The company held a conference call to discuss the results at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The press release and live audio-only webcast of the conference call can be accessed on the Nektar website: https://ir.nektar.com/. The webcast replay will be available until September 7, 2025.
For investor-related inquiries, contact Corey Davis at LifeSci Advisors, LLC: [email protected], 212-915-2577. Ahu Demir, Ph.D., can also be reached for investor inquiries at [email protected] and 212-915-3820. For media inquiries, Madelin Hawtin can be contacted at [email protected] and 603-714-2638.
Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase 2b clinical trials. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist, in several ongoing clinical trials in collaboration with various partners.
Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
For further information, visit
Howard Robin, President and Chief Executive Officer, will host a conference call to review the results. To access the conference call by phone, registrants should pre-register at Nektar Earnings Call Registration. The financial results announcement will be after the close of U.S.-based financial markets.
Cision PR Newswire is the issuing service for the press release, and the contact email for Cision PR Newswire is [email protected]. The press release was originally sent by Cision PR Newswire on behalf of Nektar Therapeutics.
- Despite the financial results announcement from Nektar Therapeutics being primarily focused on business and personal-finance aspects, their pipeline also includes exciting technologies such as the bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs.
- In the realm of personal-finance and investing, investors seeking more information about Nektar Therapeutics can contact Corey Davis at LifeSci Advisors, LLC or Ahu Demir, Ph.D., both of whom are accessible via email and telephone.
- As clouds of uncertainty surrounding the biotech industry continue to dissipate, technology-driven advancements in healthcare, such as Nektar's cloud-available webcast of the conference call discussing their financial results, are proving to be game-changers in the news sphere.
